Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma
Immunocore Limited, a leading T cell receptor biotechnology company, and Pulse Infoframe, Inc. (Pulse), a data aggregation and analytics company, today announce plans to support the first global patient registry in uveal melanoma (UM), a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment.1 The insights gained through the academic registry will provide a more comprehensive understanding of the disease and may help to shape the way future research is conducted.
The registry will include institutions from across the US, UK and Australia, and is currently being developed by leaders in the field of uveal melanoma, including:
- Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, Columbia University, US
- Joseph Sacco, PhD, Clinical Senior Lecturer at the University of Liverpool and Honorary Consultant in Medical Oncology at Clatterbridge Cancer Centre, UK
- Anthony Joshua, MBBS, PhD, Director of Cancer Services at St Vincent's Hospital and conjoint Associate Professor with the University of New South Wales, Australia
“The rarity of uveal melanoma makes it difficult to collect the data needed to better understand how the disease manifests and evolves, and who is likely to respond to treatment and why,” said Dr. Carvajal. “For the first time we’ll have the opportunity to prospectively collect and analyse global real-world data, including patient-reported outcomes. This will help to guide medical research, innovative trial design and recruitment, potentially paving the way for accelerated treatment advances.”
Research generated from the registry will examine risk factors, genetics, epidemiology, treatment cost-effectiveness and real-world outcomes from a database of patients with uveal melanoma. The goal is to create a benchmark framework, or ecosystem, for collecting and assessing clinical outcomes, as well as providing necessary data for future genetic, sub-phenotype and biomarker research.
“We’re excited to be working with the research community to address the need for a more comprehensive understanding of uveal melanoma,” said Mohammed Dar, MD, Head of Clinical Development and Chief Medical Officer at Immunocore. “We believe that this registry will provide critical insight that may help to advance the development of future treatments, including clinical and genetic information about potential subsets of people living with this devastating disease.”
Enrolment into the registry is expected to begin in August at five sites in the US, three sites in the UK, and three sites in Australia.
“At Pulse, we strive to support the entire ecosystem that researchers, clinicians and patients require to generate the real-world evidence necessary to advance clinical outcomes, support patient advocacy and promote disease awareness,” said Femida Gwadry-Sridhar, RPh, PhD, CEO and Founder at Pulse. “We are pleased to partner with Immunocore and key academic leaders on this patient registry, which will provide a detailed look into uveal melanoma from a global perspective.”
About Uveal Melanoma
Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment.1 Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases/year in the US).1,2,3,4 Up to 50% of people with uveal melanoma will eventually develop metastatic disease.1 When the cancer spreads beyond the eye, only approximately 40% of patients will survive for one year.1
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies that have the potential to transform patients’ lives. The Company’s primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.
About Pulse Infoframe, Inc. (Pulse)
Focusing on rare disease and cancer, Pulse is a new style informatics company delivering real-world insights and precision knowledge through dynamic analytics and data visualization to accelerate time-to-value. Pulse aggregates data, including patient reported outcomes, from multiple sources making it available to researchers and relevant stakeholders and offers numerous benefits including dramatically improved collaboration, informing decision making and leading to advances in treatment. Pulse is headquartered in Canada, with offices in the United States, and the United Kingdom. For more information, please visit www.pulseinfoframe.com.
1 Carvajal, RD, Schwartz, GK, Tezel, T, et al., 2017. Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 101(1), 38-44.
2 Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743.
3 Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6(7):1230-1244.
4 About ocular melanoma. Ocular Melanoma Foundation website. www.ocularmelanoma.org/about-om.htm. Accessed May 2019.
Louise Conlon, External Affairs and Brand Communications Manager
T: +44 (0) 1235 438600
Follow on Twitter: @Immunocore
Syneos Health Communications (Tebentafusp/IMCgp100)
T: +973 477 1814
Tamara Howard, PhD, Vice President of Patient Advocacy
T: +888 787 8573
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Softomotive Named a Strong Performer Among Robotic Process Automation Vendors by Independent Research Firm23.10.2019 16:18:00 CEST | Press release
Softomotive announced today it has been positioned as a Strong Performer in The Forrester Wave™: Robotic Process Automation, Q4 2019 report. According to the Forrester report, Softomotive received the highest possible score in three categories, including the Innovation/market approach/access to capital, product roadmap and differentiation, and Enterprise RPA customers criteria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191023005637/en/ Softomotive Named a Strong Performer in The Forrester Wave™: Robotic Process Automation, Q4 2019 report. According to the Forrester report (Graphic: Business Wire) Softomotive believes that this report arrives at a time of huge growth in the category, with companies focused on not only adopting RPA technology, but being concerned about how to scale and empower their workforce. This shift has driven a 2x increase in customer count year over year for Softomotive as it expands its global rea
Citi, OPIC and Ford Foundation Launch Scaling Enterprise, a $100MM Financing Partnership to Support Social Enterprises23.10.2019 16:00:00 CEST | Press release
Citi Inclusive Finance, the Overseas Private Investment Corporation (OPIC) and the Ford Foundation today introduced Scaling Enterprise, a $100 million loan guarantee facility, which will enable Citi to provide early-stage financing in local currency to companies that expand access to products and services for low-income communities in emerging markets. The announcement was made at the 2019 SOCAP Conference. Loans and working capital in local currency and at affordable rates can enable early-stage social impact companies to achieve scale, greater efficiencies and lower costs. Scaling Enterprise will facilitate vital growth financing to eligible companies that are expanding access to finance, agriculture, energy, affordable housing, water and sanitation to low-income households in emerging markets. Marking the first two transactions under Scaling Enterprise, the partners have committed $5 million in financing to INI Farms to help smallholder banana and pomegranate farmers in India access
Velodyne Announces ADAS Collaboration with Hyundai Mobis23.10.2019 12:00:00 CEST | Press release
Velodyne Lidar, Inc. today announced an agreement with Hyundai Mobis to launch a new lidar-based advanced driver assistance system (ADAS) that integrates Velodyne lidar technology and Hyundai Mobis cognitive software. The Velodyne Velarray™-based system is designed specifically for ADAS in consumer vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191023005425/en/ Velodyne Lidar announced an agreement with Hyundai Mobis to launch a new lidar-based ADAS system that integrates Velodyne lidar technology and Hyundai Mobis cognitive software. (Photo: Velodyne Lidar). "Hyundai Mobis is delighted to cooperate with Velodyne Lidar, one of the industry's most innovative lidar sensor providers, to launch a lidar system that is essential in high level autonomous driving," said Ko Youngsuk, Head of the Hyundai Mobis Strategy Planning division. "The Velarray, utilizing Velodyne’s industry-leading sensing technology, meets the deman
GSMA and Sónar Release First Details of xside23.10.2019 11:00:00 CEST | Press release
The GSMA’s successful Four Years From Now (4YFN) start-up platform and Sónar, the international festival devoted to advanced music, creativity and technology, today announced further details of their hotly anticipated co-curated event, xside. Taking place within the 4YFN venue, from 24-26 February 2020 at Fira Montjuïc, in parallel to 4YFN and MWC Barcelona 2020, xside is a new gathering including conference, networking and music to explore the role technology, design and innovation play in the future of creativity, cultures and business. As the creative heart of 4YFN and MWC Barcelona, xside is designed to create links between Sónar’s audience of creative communities, and the technological and entrepreneurial attendees of the world’s largest mobile event. It is the first integrated convergence event of its kind on this scale, co-created by leading event brands of music, creativity, technology, design and entrepreneurship. xside will welcome over 25,000 attendees across three days and
SES and Thales Reach Record Speed and Enhanced Coverage via Integrated GEO/MEO Network, Raise Bar for Inflight Connectivity23.10.2019 06:55:00 CEST | Press release
SES and Thales have taken inflight connectivity to a new level, successfully demonstrating uninterrupted access to high-throughput broadband applications for the first time over a platform supporting multi-orbit interoperability, switching seamlessly between SES’s geostationary (GEO) and O3b medium earth orbit (MEO) satellite beams. The demo flight from Melbourne, Florida to the Atlantic coast of Nicaragua saw dozens of switches successfully completed between GEO and MEO beams, and between multiple MEO satellites within a beam, using the Hughes JUPITER(TM) Aeronautical system high performance airborne modem system, SES and Thales announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191022006244/en/ SES and Thales Reach Record Speed and Enhanced Coverage via Integrated GEO/MEO Network, Raise Bar for Inflight Connectivity (Photo: Business Wire) Engineers aboard the test flight were able to simultaneously use a broad
REE Cooperates with Hino Motors to Showcase New FlatFormer Concept Vehicle at the 46th Tokyo Motor Show23.10.2019 06:30:00 CEST | Press release
Tokyo Motor Show – Today, REE announced its cooperation with Hino Motors, a leading provider of commercial vehicles, and showcased its technology within Hino’s new FlatFormer modular concept model, a super-flexible chassis that optimizes electric mobility solutions, at the 46th Tokyo Motor Show. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191022006241/en/ (Photo: Business Wire) REE’s corner module technology plays an important role to the FlatFormer concept design. FlatFormer leverages REE’s unique technology, which allows the entire drive components to reside within the wheel housing, thus creating a fully flat chassis. With the contribution of REE’s novel electric solution, Hino’s light duty FlatFormer chassis delivers optimized space, flexibility and energy efficiency to customers. [SO2] It supports a diverse range of plug-and-play body configurations that optimize internal vehicle space and provide room for additional